Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Scilex's total debt was $80.81M at Jun 30, 2026. For fiscal 2025 it was $83.26M, up 138.7% from the year before. The highest annual figure on record is $108.43M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.26M | +138.7% |
| FY2024 | Dec 31, 2024 | $34.88M | -67.8% |
| FY2023 | Dec 31, 2023 | $108.43M | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2021 | Dec 31, 2021 | $29.14M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $80.81M | +102.7% |
| Q1 FY2026 | Mar 31, 2026 | $80.78M | +104.8% |
| Q4 FY2025 | Dec 31, 2025 | $83.26M | +138.7% |
| Q3 FY2025 | Sep 30, 2025 | $45.67M | -46.0% |
| Q2 FY2025 | Jun 30, 2025 | $39.87M | -47.1% |
| Q1 FY2025 | Mar 31, 2025 | $39.44M | -57.6% |
| Q4 FY2024 | Dec 31, 2024 | $34.88M | -67.8% |
| Q3 FY2024 | Sep 30, 2024 | $84.64M | -26.5% |
| Q2 FY2024 | Jun 30, 2024 | $75.37M | – |
| Q1 FY2024 | Mar 31, 2024 | $92.92M | +218.9% |
| Q4 FY2023 | Dec 31, 2023 | $108.43M | – |
| Q3 FY2023 | Sep 30, 2023 | $115.22M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $29.14M | – |